Adeona reports $979.

Analysis and development expenses were $562,748 and $981,691, respectively, for the three and half a year ended June 30, 2010, compared to $405,645 and $901,639 for the same periods in ’09 2009. These raises are primarily due to the increased costs from the procedure of Adeona Clinical Laboratory, which was acquired in the 3rd quarter of 2009 and therefore did not have any impact on our expenses through the 1st and second quarter of 2009. Research and development expenditures for the three and six months ended June 30, 2010, also include a noncash charge of $18,487 and $52,967, compared to $63,293 and $119,610 for the same period in ’09 2009, relating to share-based compensation expense.Karsten Fischer, BioMedPartners AG commented. ‘Together with the unique small volume format, this technique is enabling research, advancement and potential diagnostic queries even, so far inaccessible.’ Alec Rauschenbusch, Controlling Partner of Grazia Collateral GmbH: ‘With its highly innovative multiplexing program, AYOXXA is setting fresh requirements for applications and analysis of high-value biological samples in the region of medical study and pharmacological screening.’ Additionally, the business announces that Andreas Richter will take over the function as CFO in AYOXXA's Executive Management Group, effective January 1st 2015.